[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"anemia-of-pregnancy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:anemia-of-pregnancy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,70],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100514376","hemoglobin-testing-in-pregnant-patients-100514376",false,"NCT05977686","Hemoglobin Testing in Pregnant Patients","Point-Of-Care Anemia Testing in Pregnant Patients - A Prospective Observational Study","AnemiaPOC","Inclusion Criteria:\n\n* Pregnant women ages 18-50 years old\n\nExclusion Criteria:\n\n* Patients with hemoglobinopathies (qualitative defects, sickle-cell anemia) and hemoglobin synthesis disorders (quantitative defects such as thalassemia)\n* Patients with peripheral vascular diseases and skin conditions that affect blood vessels in the digit\n* Patients with hyperbilirubinemia",true,"FEMALE","18 Years","50 Years",{"count":22,"type":23},250,"ESTIMATED","OBSERVATIONAL","The project is a prospective observational study aimed to assess and to validate the use of point-of-care hemoglobin testing in pregnancy. Point-of-care hemoglobin testing has the potential to (1) increase access to hemoglobin monitoring in pregnancy in low resource settings, (2) increase availability of hemoglobin monitoring in anemic patients, and (3) provide immediate results for real-time patient counseling and intervention. However, to date, point-of-care hemoglobin testing devices have not yet been studied for use in an ambulatory obstetric population. The Masimo device is a Root Radical 7 Pulse CO-Oximeter, manufactured by Masimo, Inc. This device is non-invasive and placed externally on a patient's finger to generate an estimation of a patient's hemoglobin value. The HemoCue® device is a minimally-invasive device that relies on the finger prick method to get a capillary hemoglobin measurement, and The Rubby is a mobile application based platform that uses a photo of the participants nailbed to estimate hemoglobin values. Participants in this study will be approached at the Obstetrics and Gynecology clinics at George Washington Medical Faculty Associates. Point-of-care hemoglobin measurements will be assessed using the non-invasive Masimo device along with minimally-invasive hemoglobin HemoCue® Hb 801 device and compared to traditional venipuncture hemoglobin testing.",[27,28],"Post Partum Hemorrhage","Anemia of Pregnancy","RECRUITING","2026-04-21",{"date":32,"type":33},"2026-04-23","ACTUAL",{"date":35,"type":33},"2025-12-03",{"date":37,"type":23},"2026-12",{"name":39,"class":40},"Inova Health Care Services","OTHER",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100383897","phase-4-early-antenatal-support-for-iron-deficiency-anemia-100383897","NCT04278651","Early Antenatal Support for Iron Deficiency Anemia","Early Antenatal Support for Iron Deficiency Anemia: A Randomized Controlled Trial of Early Initiation of Intravenous Versus Oral Iron Therapy for Treatment of Iron Deficiency Anemia in Pregnancy","EASI-A","Inclusion Criteria:\n\n* Singleton gestation\n* Gestational age \\\u003C24 weeks\n* Baseline Hb ≥9.0 and \\\u003C11.0 with evidence of iron deficiency anemia\n\nIron deficiency anemia diagnosed (at any point in patient history) by:\n\n* Hb\\\u003C11.0\n* Ferritin\\\u003C30 and\u002For total iron saturation \\\u003C20\n\nExclusion Criteria:\n\n* Sickle cell Disease (NOT sickle cell trait)\n* Evidence of acute anemia requiring transfusion or IV iron therapy\n* Major congenital or chromosomal anomaly\n* Previous use of IV iron in this pregnancy\n* Severe cardiac, renal, or liver disease\n* Autoimmune disease (ie Systemic Lupus Erythematosus (SLE)\n* Allergy or contraindication to either study drug\n* History of medication allergy, reaction to IV infusion, or reaction to Feraheme or other IV iron products","65 Years",{"count":52,"type":23},80,"INTERVENTIONAL",[55],"PHASE4","This is a randomized, controlled multi-site trial of iron therapy in pregnancy. The purpose of this research is to see if second trimester initiation of intravenous (IV) iron therapy is better than oral iron therapy for treatment of anemia in pregnancy by improving blood count, quality of life and reducing side effects.",[58,59,28],"Pregnancy Related","Anemia, Iron Deficiency","2025-11-25",{"date":62,"type":33},"2025-12-02",{"date":64,"type":33},"2021-09-29",{"date":66,"type":23},"2026-12-30",{"name":68,"class":40},"Thomas Jefferson University",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":78,"enrollmentInfo":79,"targetDuration":81,"studyType":24,"phases":4,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100567504","liposomal-iron-30-mg-supplement-in-non-anemic-pregnant-females-100567504","NCT06669052","Liposomal Iron 30 mg Supplement in Non-anemic Pregnant Females","Liposomal Iron 30 mg Supplement in Non-anemic Pregnant Females an Observational Study","LITSNPF","Inclusion Criteria:\n\n* Pregnant females; gestational age from 14 to 16 weeks Age 18-45 years\n* Low-risk pregnancy is defined as a pregnancy in which there is no high risk of problems or unfavorable outcomes, and the expectant mother and fetus are typically healthy\n* Non-anemic women at the time of recruitment (hemoglobin level not less than 10.5. Hemoglobin measured within 2 or 3 weeks of recruitment\n* Singleton pregnancy\n* Agree to participate in the study including data collection from medical records and participation in related questionnaires.\n\nExclusion Criteria:\n\n* Inadequate medical records\n* Pregnant women living in areas away from the recruitment center\n* Had any chronic health problem.\n* Women with any form of hereditary anemia including sickle cell anemia, thalassemia, and Glucose-6-phosphate dehydrogenase (G6PD) deficiency.\n* History of antepartum bleeding\n* Refuse to sign the informed consent.","45 Years",{"count":80,"type":23},714,"90 Days","Protocol Summary: Liposomal Iron Supplementation in Non-anemic Pregnant Females This observational study aims to evaluate the efficacy and safety of daily liposomal iron supplementation (30 mg) in non-anemic pregnant women during their second trimester of pregnancy. The study will focus on pregnant females aged 18-45 years with low-risk, singleton pregnancies who are non-anemic (hemoglobin ≥10.5) at 14-16 weeks gestation.\n\nPrimary Research Question:\n\nDoes daily supplementation with 30 mg liposomal iron effectively maintain maternal hemoglobin levels over 90 days? Measured by: The difference in maternal hemoglobin levels between baseline and after 90 days of treatment in women recruited at 14-16 weeks gestation.\n\nSecondary Research Questions:\n\nWhat are the effects of liposomal iron supplementation on serum ferritin levels? Measured by: Changes in serum ferritin levels between baseline and after 90 days of treatment.\n\nWhat is the safety profile of liposomal iron supplementation during pregnancy? Measured by: Maternal gastrointestinal side effects monitored at each prenatal visit (day 30, 60, and 90).\n\nWhat is the compliance rate with liposomal iron supplementation? Measured by: Participant-reported compliance assessed at each prenatal visit (day 30, 60, and 90).\n\nParticipants will:\n\nReceive daily liposomal iron supplementation (30 mg) for 90 days. Attend regular prenatal visits for monitoring at days 30, 60, and 90. Complete questionnaires about compliance and any adverse effects at each visit. Undergo blood tests to measure hemoglobin and serum ferritin levels at baseline and day 90.\n\nThis multi-center study will involve 714 participants across 100 sites, with recruitment beginning in November 2024 and study completion expected by July 2025. The study's findings will contribute to understanding the role of liposomal iron supplementation in preventing iron deficiency during pregnancy and its potential advantages over traditional iron supplements in terms of tolerability and compliance.",[28,84],"Iron Deficiency Anemia",[86,87,88,89,90],"30 mg liposomal irom","non-anemic pregnant females","observational study","hemoglobin level","Second trimester","NOT_YET_RECRUITING","2024-10-31",{"date":94,"type":33},"2024-11-01",{"date":94,"type":23},{"date":97,"type":23},"2025-05",{"name":99,"class":100},"Orchidia pharmaceutical Industries","INDUSTRY"]